Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 406

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 406
---
 12 months £’000 |     |             Between 
 1 and 2 years £’000 |     |     Between 
     2 and 5 
 years £’000 |     | Over          
 5 years £’000 |
| Trade and other payables |     |        1,173 |     |                             – |     |                   – |     |           – |     | –             |
| Lease liabilities        |     |           49 |     |                           140 |     |                 188 |     |         254 |     | –             |
| Total                    |     |        1,222 |     |                           140 |     |                 188 |     |         254 |     | –             |

| 2021                     |     |      Up to 3 
 months £’000 |     | Between 3 and 12 months £’000 |     |             Between 
 1 and 2 years £’000 |     |     Between 
     2 and 5 
 years £’000 |     | Over          
 5 years £’000 |
| Trade and other payables |     |        1,036 |     |                             – |     |                   – |     |           – |     | –             |
| Lease liabilities        |     |           46 |     |                           171 |     |                 195 |     |         442 |     | –             |
| Total                    |     |        1,082 |     |                           171 |     |                 195 |     |         442 |     | –             |

More details with regard
to the line items above are included in the respective notes:

| · | Trade and other payables – note 15 |

| · | Borrowings – note 16 |

As a result of
the Strategic Review undertaken in March 2020 the Group repaid all Government Research loans during 2020 and 2021.

| F-66 |

| 19 | Financial instruments – risk management (continued) |

Capital risk management

The Group monitors capital
which comprises all components of equity (i.e. share capital, share premium, foreign exchange reserve and accumulated deficit).

The Group’s objectives
when maintaining capital are:

| · | to safeguard the entity’s ability to continue as a going concern; and |

| · | to have sufficient resource to take development projects forward towards commercialisation. |

The Group continues
to incur substantial operating expenses. Until the Group